Patent term extensions and exclusivity amid blockbuster drug patent expirations
As 10 blockbuster drug patents expire, do pharma companies need to focus even more on patent term extensions & exclusivity strategy?
Trade secrets - the forgotten IP right
In this article written for FMCG CEO, Sarah explains how to identify a trade secret and - most importantly - how to keep it.
Is AI about to revolutionise foodtech?
In this special report we will examine which areas of food manufacture are benefiting from the introduction of AI and ML and look at the key considerations for maximising the value of the underlying innovation.
Could Patent Box reduce your Corporation Tax bill?
If you have created or developed a patented invention or a product that uses patented innovation, you may be eligible to use Patent Box to reduce your Corporation Tax bill.
LATEST INSIGHTS
Hidden Value: The digital IP you didn't realise you have
Today every business is a digital business. If you don’t believe me, think about the following scenarios:
Plausible or not? EPO’s Enlarged Board of Appeal leaves us in the dark on post-filed data and inventive step
The EPO’s Enlarged Board of Appeal has attempted to clarify the law concerning the doctrine of ‘plausibility’ and the use of post-filed data to support inventive step. The questions answered are of particular relevance to those in the life science sector.
More drama for combination SPCs
The stage is set for another referral to the Court of Justice of the EU on the eligibility criteria for Supplementary Protection Certificates for “combination products” - those comprising two or more active ingredients.
Where IP strategy meets a passion for synthetic biology
Discover CleanTech spoke to Potter Clarkson patent attorney Sara Holland about her passion for synthetic biology, the work of a patent attorney, and why scientists need solid IP strategies to change the world for the better.
Introducing Anna Johnson Aspberg
Anna has just joined Potter Clarkson this summer and Potter Clarkson’s Tom Harding sat down to chat with her at the Nordic Life Science Days conference.
WTO's COVID deal: more vaccine ‘enabler’ than IP waiver?
In this article by Sarah Speight, Sheena Linehan has been quoted alongside the director of IP at the World Trade Organisation and the global patent head of an international law firm.
Exclusivity, patent licensing and the UPC
Dave Holt, senior associate and licensing specialist, comments on the recent Court of Appeal decision Neurim v Generics [2022] EWCA Civ 359 and its implications on licensing Unitary Patents.
Can patent term extensions pull pharma companies back from the edge of the ‘patent cliff’?
According to many, the anticipated arrival of Humira biosimilars in the US next year has pushed AbbVie's drug to the precipice of the pharma industry’s biggest-ever patent cliff.
Are you ready for the ‘big bang’?
Patent Offices around the world are busy preparing for the ‘big bang’ date of 1 July 2022 on which the new international standard for providing sequence listings (Standard ST.26) will come into force, simultaneously replacing existing Standard ST.25. Applicants and their representatives will need to be aware of the change and its consequences to avoid difficulties.
Aarhus Investor Summit
Aarhus Investor Summit | Science Edition is taking place at INCUBA Navitas in central Aarhus on 18 May 2022. This event connects investors with early stage spinouts and researchers looking to commercialize research-based inventions and solutions.
LSX World Congress
LSX World Congress is taking place in London, UK on 10-11 May 2022. This event gathers the founders and CEOs of innovative biotech, medtech and healthtech start-ups through to healthcare giants, and everyone in between.